W Richard Staub Sells 5,500 Shares of IQVIA (NYSE:IQV) Stock

IQVIA Holdings Inc. (NYSE:IQV) insider W Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

IQVIA Price Performance

Shares of NYSE:IQV opened at $236.07 on Thursday. The stock has a market cap of $38.86 billion, a price-to-earnings ratio of 29.29, a PEG ratio of 1.94 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36. The stock’s 50 day moving average price is $198.78 and its 200 day moving average price is $186.63.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a share repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of the stock. Apella Capital LLC raised its holdings in shares of IQVIA by 5.1% during the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after acquiring an additional 58 shares during the period. Quadrant Capital Group LLC raised its stake in shares of IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares during the period. Private Advisor Group LLC boosted its position in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the period. Brookstone Capital Management raised its position in IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after buying an additional 63 shares during the last quarter. Finally, Breakwater Capital Group lifted its stake in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after acquiring an additional 64 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA exceeded second-quarter expectations, reporting adjusted EPS of $3.15 versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion. Revenue increased 8.7% year over year, while full-year 2026 EPS guidance was set at $12.80–$13.00. Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
• Positive Sentiment: Record bookings and a sizable backlog improve visibility into future revenue growth. Investors are now focused on how effectively IQVIA converts that backlog into sales and earnings. The Backlog Tells the Real Story: Inside IQVIA’s Blowout Q2
• Positive Sentiment: IQVIA and Medera announced a collaboration involving cardiac gene therapy and human-based drug discovery. The agreement could expand IQVIA’s role in specialized clinical development, though the financial impact is likely longer term. IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
• Positive Sentiment: The company’s previously authorized $2 billion share-repurchase program, representing up to 6.8% of shares, provides potential support for EPS and signals management’s confidence in the valuation.
• Neutral Sentiment: Analysts remain generally constructive, with a consensus “Moderate Buy” rating and an average price target of $241.88. However, commentary highlights execution risk following the recent rally, particularly the pace of backlog conversion. Five Insightful Analyst Questions From IQVIA’s Q2 Earnings Call
• Negative Sentiment: Insider selling may weigh modestly on sentiment. Bhavik Patel sold 1,855 shares for approximately $436,000, reducing his position by 57.91%, while W. Richard Staub sold 5,500 shares for about $1.28 million, cutting his holdings by 29.24%. These sales do not necessarily signal weakening fundamentals. IQVIA Insider Selling
• Negative Sentiment: IQVIA’s debt-to-equity ratio of 2.18 and current ratio of 0.71 underscore leverage and liquidity concerns. Continued earnings growth and disciplined execution are important to support the company’s valuation.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HSBC restated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Evercore reissued an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Royal Bank Of Canada increased their price objective on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.